AG
Artal Group Portfolio holdings
AUM
$930M
1-Year Return
3.57%
This Quarter Return
+49.95%
1 Year Return
-3.57%
3 Year Return
+157.23%
5 Year Return
+160.22%
10 Year Return
+1,359.85%
AUM
$2.93B
AUM Growth
+$639M
(+28%)
Cap. Flow
-$173M
Cap. Flow
% of AUM
-5.9%
Top 10 Holdings %
Top 10 Hldgs %
77.18%
Holding
114
New
14
Increased
16
Reduced
25
Closed
23
Top Buys
| 1 |
argenx
ARGX
|
$44.3M |
| 2 |
Scholar Rock
SRRK
|
$41.4M |
| 3 |
Arrowhead Research
ARWR
|
$31.3M |
| 4 |
Korro Bio
KRRO
|
$20.1M |
| 5 |
Kymera Therapeutics
KYMR
|
$18.5M |
Top Sells
| 1 |
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
|
$88.2M |
| 2 |
CERE
Cerevel Therapeutics Holdings, Inc. Common Stock
CERE
|
$69.4M |
| 3 |
Amicus Therapeutics
FOLD
|
$28.9M |
| 4 |
Cytokinetics
CYTK
|
$25.4M |
| 5 |
IMGN
Immunogen Inc
IMGN
|
$24M |
Sector Composition
| 1 | Healthcare | 51.64% |
| 2 | Consumer Discretionary | 47.64% |
| 3 | Technology | 0.45% |
| 4 | Real Estate | 0.14% |
| 5 | Communication Services | 0.09% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
26
Sea Limited
SE
$112B
| $15.1M | 0.5% |
372,000
-25,000
| -6% | -$1.01M |
|
|
HARP
27
DELISTED
Harpoon Therapeutics, Inc. Common Stock
HARP
| $14.8M | 0.49% |
1,304,127
+1,204,127
| +1,204% | +$13.7M |
|
|
AGEN
28
Agenus
AGEN
$135M
| $12.9M | 0.43% |
781,562
| – | – |
|
29
Natera
NTRA
$22.8B
| $12.5M | 0.42% |
200,000
| – | – |
|
30
Roivant Sciences
ROIV
$8.83B
| $11.2M | 0.37% |
1,000,000
| – | – |
|
31
Gossamer Bio
GOSS
$623M
| $11M | 0.37% |
12,058,968
+5,659,149
| +88% | +$5.16M |
|
32
Schrodinger
SDGR
$1.41B
| $10.7M | 0.36% |
300,000
-200,000
| -40% | -$7.16M |
|
33
Erasca
ERAS
$445M
| $10.1M | 0.33% |
4,721,194
| – | – |
|
|
FUSN
34
DELISTED
Fusion Pharmaceuticals Inc. Common Shares
FUSN
| $9.66M | 0.32% |
1,005,500
-719,500
| -42% | -$6.91M |
|
35
Seer Inc
SEER
$114M
| $9.22M | 0.31% |
4,750,000
| – | – |
|
36
Lexeo Therapeutics
LXEO
$279M
| $8.1M | 0.27% |
+603,435
| New | +$8.1M |
|
|
CNTA
37
Centessa Pharmaceuticals
CNTA
$2.16B
| $8.06M | 0.27% |
+1,012,500
| New | +$8.06M |
|
38
Ovid Therapeutics
OVID
$86.8M
| $8.05M | 0.27% |
2,500,000
| – | – |
|
|
CBAY
39
DELISTED
Cymabay Therapeutics
CBAY
| $7.17M | 0.24% |
+303,600
| New | +$7.17M |
|
40
TSMC
TSM
$1.24T
| $7.07M | 0.24% |
67,999
-34,700
| -34% | -$3.61M |
|
41
Taysha Gene Therapies
TSHA
$903M
| $6.48M | 0.22% |
3,663,104
| – | – |
|
42
Cartesian Therapeutics
RNAC
$273M
| $6.3M | 0.21% |
304,555
| – | – |
|
|
VIGL
43
DELISTED
Vigil Neuroscience
VIGL
| $6.12M | 0.2% |
1,811,191
-96,944
| -5% | -$328K |
|
44
Black Diamond Therapeutics
BDTX
$167M
| $5.75M | 0.19% |
2,046,517
| – | – |
|
45
Solid Biosciences
SLDB
$435M
| $5.58M | 0.19% |
909,219
| – | – |
|
46
Vor Biopharma
VOR
$247M
| $5.28M | 0.18% |
2,347,424
-340,591
| -13% | -$766K |
|
47
Repare Therapeutics
RPTX
$72.6M
| $5.11M | 0.17% |
700,000
| – | – |
|
48
Sagimet Biosciences
SGMT
$230M
| $5.01M | 0.17% |
924,771
| – | – |
|
49
Pinduoduo
PDD
$178B
| $4.76M | 0.16% |
+32,500
| New | +$4.76M |
|
50
Foghorn Therapeutics
FHTX
$321M
| $4.65M | 0.15% |
720,720
-1,000,000
| -58% | -$6.45M |
|